ArticleCancer science2026
LAMC2
Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Laminin subunit gamma 2 (LAMC2) is a molecule related to the extracellular matrix. It plays a vital role in many cancers. But its effect in bladder cancer (BCa) is still undefined. This study was aimed at exploring the biological function, downstream mechanism, and therapeutic potential of LAMC2 in BCa. We combined single-cell RNA sequencing data from 13 BCa samples and data from TCGA-BLCA, GSE13507, and IMvigor210 cohorts. Bioinformatics analyses were carried out, including epithelial cell subclustering, pathway enrichment, GSVA, HdWGCNA, and RNA sequencing. The expression of LAMC2 in BCa tissues was confirmed through immunohistochemistry and immunofluorescence. Then shRNA was used to knock down LAMC2 in 5637 and T24 cells to test its effects in vitro and in vivo. These results were also tested in a xenograft tumor model. Potential inhibitors of LAMC2 were screened by molecular docking and in vitro experiments. We found that LAMC2 was enriched in a malignant epithelial cell subgroup and was linked to higher tumor grade, advanced tumor stage, poor prognosis and inferior response to immunotherapy. LAMC2 regulated bladder cancer cell proliferation, migration, and invasion through the SerpinB3/STAT3/CD44 axis based on the results of in vitro and single-cell analysis. Diosmetin was found to suppress LAMC2-related signaling in bladder cancer cells, providing a new strategy for BCa treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.